Ashford Dunwoody Path's Phase 1 ribbon cutting
The Brief
The newly completed Ashford Dunwoody Path includes a two-way raised cycle track, ADA-compliant sidewalk, and new bus shelter, with additional upgrades like pedestrian lighting and decorative elements funded by PCIDs.
Phase 1 of the path runs from Hammond Drive to Perimeter Center West, costing $1.5 million, split between the City and PCIDs, with the City's contribution from hotel/motel tax revenue.
The project will proceed with Phase 2, extending the path north to Ashford Center Parkway, currently in the right-of-way acquisition stage.
DUNWOODY, Ga. - The city of Dunwoody is celebrating as it opens a major segment of its Ashford Dunwoody Path.
A ribbon cutting hosted by city leaders and officials from the Perimeter Community Improvement Districts was held this week to official open Phase 1.
What we know
The newly completed section includes a two-way raised cycle track separated from traffic by a landscaped buffer, a wider ADA-compliant sidewalk, and a new bus shelter. Additional upgrades include pedestrian lighting, improved landscaping, and decorative pavers and street furniture funded by PCIDs.
Local perspective
The path runs along Ashford Dunwoody Road from Hammond Drive to Perimeter Center West, directly in front of Perimeter Mall. It is part of Dunwoody's long-range Transportation Plan and Trail Master Plan, designed to create safer, more accessible connections throughout the Perimeter Center area.
By the numbers
Construction of Phase 1 cost $1.5 million, split evenly between the City and PCIDs. The City's contribution came from hotel/motel tax revenue, while PCIDs also fully covered the aesthetic enhancements.
What they're saying
"This milestone project marks a significant step forward in the City's commitment to improving connectivity in Dunwoody's Perimeter Center," said city officials. "It also reflects the power of partnership and shared investment."
What's next
The project will continue with Phase 2, which will extend the path north to Ashford Center Parkway. That segment is currently in the right-of-way acquisition stage.
The Source
The city of Dunwoody and the Perimeter Community Improvement Districts provided the details and photos for this article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Walton County to break ground on Driftwood Road
WALTON COUNTY, Fla. (WMBB) – The Walton County Board of County Commissioners and the Walton County Beach Operations and Tourism Departments plan to break ground on the Driftwood Road Municipal Parking facility. According to a news release, the construction will begin Monday, June 16, on 76 Driftwood Road in Miramar Beach at 9 a.m. U.S. 231 Road Improvement Project to begin in Bay County Walton County's need for public beach access, rest areas and transit stops led to the project approval from the BCC. The Driftwood Road Municipal Parking facility will include 67 parking spaces with dedicated ADA, LSV and bicycle parking. Four of the parking spots will also include electric vehicle charging stations. Officials say the construction of the 1.119-acre lot will take approximately 11 months. For visitors, the public transit stop will have air-conditioning as well as a restroom facility for convenience. The Tourist Development Tax, a 5% tax collected on short-term rentals in south Walton County, funds this development. For more information and project updates, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
7 hours ago
- Yahoo
City to activate rideshare hub by UTEP, Cincinnati Entertainment District
EL PASO, Texas (KTSM) — Signage designating a new rideshare hub will be installed on Monday, June 9, on the 200 block of W. Baltimore Drive, near the University of Texas at El Paso (UTEP) and the Cincinnati Entertainment District, the City of El Paso said in a news release. This initiative, which is part of the City's Social City Assessment Plan, was designed to improve public safety and expand transportation options in the Kern Place neighborhood, the City said. The City said the new rideshare hub is 'well-lit and equipped with security cameras, providing a safe and clearly designated location for rideshare and taxi services to pick up and drop off passengers.' The hub will be operational on Monday afternoon, immediately following the installation signage, the City said. The City said key benefits of the hub include: More organized and efficient passenger pick-ups and drop-offs; Reduced congestion caused by drivers circling the area or blocking traffic lanes; Enhanced safety through ride verification, helping riders ensure they are entering the correct vehicle. 'City officials encourage residents and visitors to begin using the Rideshare Hub, particularly those planning to attend the Coldplay concert at the Sun Bowl this weekend,' read the news release. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
7 hours ago
- Yahoo
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking place June 20-23, 2025 in Chicago, IL. Presentation details: Symposium Title: Joint ADA/IPITA Symposium: Outpacing the Immune System—Sprinting Towards Immune Protection for Cell Replacement Therapy Presentation Title: Hypoimmune Pancreatic Islet Transplantation in Adult Subjects with Type 1 Diabetes Presentation Date: Monday, June 23, 2025 Presentation Time: 9:00 – 9:20 a.m. CT Location: W192 A-C About Sana Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA and Bothell, WA. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about Sana Biotechnology, Inc. (the 'Company,' 'we,' 'us,' or 'our') within the meaning of the federal securities laws, including those related to the company's vision and expectations regarding participation in and the presentation at the 85th Annual American Diabetes Association Scientific Sessions, including the content of such presentation. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'design,' 'due,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'positioned,' 'potential,' 'predict,' 'seek,' 'should,' 'target,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company's current and future research and development programs, preclinical and clinical trials, as well as economic, market, and social disruptions. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's Securities and Exchange Commission reports, including but not limited to its Quarterly Report on Form 10-Q dated May 8, 2025. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. Investor Relations & Media:Nicole
